辅助生殖技术中卵母细胞、胚胎和囊胚冷冻保存:系统综述与Meta分析比较慢速冷冻与玻璃化以支持全球指南制定
系统综述与Meta分析比较慢速冷冻与玻璃化冷冻卵母细胞、胚胎和囊胚的临床结局。玻璃化组卵母细胞持续临床妊娠率每周期显著更高(RR=2.81),胚胎玻璃化每周期临床妊娠率接近显著(RR=1.89,P=0.051),胚胎冷冻存活率玻璃化显著更优(RR=1.59)。证据质量低至中等,作者建议继续使用慢速冷冻的实验室应考虑过渡到玻璃化。
要点
- 卵母细胞玻璃化每周期持续临床妊娠率高于慢速冷冻(RR=2.81,95%CI 1.05-7.51,P=0.039)。
- 胚胎玻璃化每周期临床妊娠率与慢速冷冻差异接近显著(RR=1.89,95%CI 1.00-3.59,P=0.051,I²=71.9%)。
- 胚胎玻璃化冷冻存活率显著优于慢速冷冻(RR=1.59,95%CI 1.30-1.93,P<0.001,I²=93%)。
核心结论
- 作者认为现有RCT数据提示玻璃化/复温在卵母细胞、卵裂期胚胎和囊胚的临床结局(低质量证据)和冷冻存活率(中等质量证据)方面优于慢速冷冻/解冻,结果被队列研究证实。
- 基于此证据,作者建议继续使用慢速冷冻的实验室应考虑过渡到使用玻璃化进行冷冻保存。
研究设计与样本
- 系统综述与Meta分析,检索Medline(1966年至2016年8月1日),纳入全文发表的随机对照试验和队列研究。
- 采用随机效应模型计算相对危险度(RR)和95%CI。
- 纳入1项比较卵母细胞慢速冷冻与玻璃化的RCT、1项比较玻璃化与新鲜卵母细胞的RCT、3项符合标准的胚胎冷冻保存RCT(638个卵裂期和囊胚期复温/解冻周期),无原核期胚胎。
主要发现
- 卵母细胞玻璃化与慢速冷冻比较:每周期持续临床妊娠率RR=2.81(95%CI 1.05-7.51,P=0.039,分别为48和30周期);每移植RR=1.81(95%CI 0.71-4.67,P=0.214,分别为47和19移植);每复温/解冻卵母细胞RR=1.14(95%CI 1.02-1.28,P=0.018,分别为260和238个卵母细胞)。
- 玻璃化与新鲜卵母细胞比较:每随机女性持续临床妊娠率RR=1.03(95%CI 0.87-1.21,P=0.744,每组300女性);每周期RR=1.01(95%CI 0.86-1.18,P=0.934,分别为267和259周期);每使用卵母细胞RR=1.02(95%CI 0.82-1.26,P=0.873,分别为3286和3185个卵母细胞)。
- 胚胎玻璃化与慢速冷冻比较:每周期临床妊娠率RR=1.89(95%CI 1.00-3.59,P=0.051,三项RCT,I²=71.9%);一项卵裂期胚胎RCT报告每周期活产率玻璃化更高(RR=2.28,95%CI 1.17-4.44,P=0.016,216周期)。
- 二次分析:7项RCT(3615个胚胎)汇总显示玻璃化后胚胎冷冻存活率显著改善(RR=1.59,95%CI 1.30-1.93,P<0.001,I²=93%)。
临床怎么用
- 作者建议,基于现有证据特别是冷冻存活率方面的证据,继续使用慢速冷冻的实验室应考虑过渡到使用玻璃化进行冷冻保存。
局限性
- 卵母细胞和胚胎临床结局的证据质量为低,冷冻存活率的证据质量为中等。
- 胚胎玻璃化与慢速冷冻比较每周期临床妊娠率的差异仅为边缘统计学显著(RR=1.89,95%CI 1.00-3.59,P=0.051)。
- 胚胎玻璃化与慢速冷冻比较每周期临床妊娠率的Meta分析存在异质性(I²=71.9%)。
- 胚胎冷冻存活率Meta分析存在异质性(I²=93%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Successful cryopreservation of oocytes and embryos is essential not only to maximize the safety and efficacy of ovarian stimulation cycles in an IVF treatment, but also to enable fertility preservation. Two cryopreservation methods are routinely used: slow-freezing or vitrification. Slow-freezing allows for freezing to occur at a sufficiently slow rate to permit adequate cellular dehydration while minimizing intracellular ice formation. Vitrification allows the solidification of the cell(s) and of the extracellular milieu into a glass-like state without the formation of ice. OBJECTIVE AND RATIONALE: The objective of our study was to provide a systematic review and meta-analysis of clinical outcomes following slow-freezing/thawing versus vitrification/warming of oocytes and embryos and to inform the development of World Health Organization guidance on the most effective cryopreservation method. SEARCH METHODS: A Medline search was performed from 1966 to 1 August 2016 using the following search terms: (Oocyte(s) [tiab] OR (Pronuclear[tiab] OR Embryo[tiab] OR Blastocyst[tiab]) AND (vitrification[tiab] OR freezing[tiab] OR freeze[tiab]) AND (pregnancy[tiab] OR birth[tiab] OR clinical[tiab]). Queries were limited to those involving humans. RCTs and cohort studies that were published in full-length were considered eligible. Each reference was reviewed for relevance and only primary evidence and relevant articles from the bibliographies of included articles were considered. References were included if they reported cryosurvival rate, clinical pregnancy rate (CPR), live-birth rate (LBR) or delivery rate for slow-frozen or vitrified human oocytes or embryos. A meta-analysis was performed using a random effects model to calculate relative risk ratios (RR) and 95% CI. OUTCOMES: One RCT study comparing slow-freezing versus vitrification of oocytes was included. Vitrification was associated with increased ongoing CPR per cycle (RR = 2.81, 95% CI: 1.05-7.51; P = 0.039; 48 and 30 cycles, respectively, per transfer (RR = 1.81, 95% CI 0.71-4.67; P = 0.214; 47 and 19 transfers) and per warmed/thawed oocyte (RR = 1.14, 95% CI: 1.02-1.28; P = 0.018; 260 and 238 oocytes). One RCT comparing vitrification versus fresh oocytes was analysed. In vitrification and fresh cycles, respectively, no evidence for a difference in ongoing CPR per randomized woman (RR = 1.03, 95% CI: 0.87-1.21; P = 0.744, 300 women in each group), per cycle (RR = 1.01, 95% CI: 0.86-1.18; P = 0.934; 267 versus 259 cycles) and per oocyte utilized (RR = 1.02, 95% CI: 0.82-1.26; P = 0.873; 3286 versus 3185 oocytes) was reported. Findings were consistent with relevant cohort studies. Of the seven RCTs on embryo cryopreservation identified, three met the inclusion criteria (638 warming/thawing cycles at cleavage and blastocyst stage), none of which involved pronuclear-stage embryos. A higher CPR per cycle was noted with embryo vitrification compared with slow-freezing, though this was of borderline statistical significance (RR = 1.89, 95% CI: 1.00-3.59; P = 0.051; three RCTs; I2 = 71.9%). LBR per cycle was reported by one RCT performed with cleavage-stage embryos and was higher for vitrification (RR = 2.28; 95% CI: 1.17-4.44; P = 0.016; 216 cycles; one RCT). A secondary analysis was performed focusing on embryo cryosurvival rate. Pooled data from seven RCTs (3615 embryos) revealed a significant improvement in embryo cryosurvival following vitrification as compared with slow-freezing (RR = 1.59, 95% CI: 1.30-1.93; P < 0.001; I2 = 93%). WIDER IMPLICATIONS: Data from available RCTs suggest that vitrification/warming is superior to slow-freezing/thawing with regard to clinical outcomes (low quality of the evidence) and cryosurvival rates (moderate quality of the evidence) for oocytes, cleavage-stage embryos and blastocysts. The results were confirmed by cohort studies. The improvements obtained with the introduction of vitrification have several important clinical implications in ART. Based on this evidence, in particular regarding cryosurvival rates, laboratories that continue to use slow-freezing should consider transitioning to the use of vitrification for cryopreservation.
引用
- Rienzi L, Gracia C, Maggiulli R, et al. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017. PMID: 27827818. doi:10.1093/humupd/dmw038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。